The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1776-260X

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib ; day:3 ; month:12 ; year:2020 ; pages:1-8
Targeted oncology ; (3.12.2020), 1-8

Creator: Buder, Anna
Hochmair, Maximilian J.
Filipits, Martin

Contributor: SpringerLink (Online service)

DOI: 10.1007/s11523-020-00781-3

URN: urn:nbn:de:101:1-2021011218470924265752

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:32 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Buder, Anna
Hochmair, Maximilian J.
Filipits, Martin
SpringerLink (Online service)

Other Objects (12)

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer

Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer

Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer

Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer

Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer

Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer

Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

Related objects

Reset password